DK1817343T3 - Humane monoklone antistoffer mod humant IL-4 - Google Patents

Humane monoklone antistoffer mod humant IL-4

Info

Publication number
DK1817343T3
DK1817343T3 DK05769838.3T DK05769838T DK1817343T3 DK 1817343 T3 DK1817343 T3 DK 1817343T3 DK 05769838 T DK05769838 T DK 05769838T DK 1817343 T3 DK1817343 T3 DK 1817343T3
Authority
DK
Denmark
Prior art keywords
human
monoclonal antibodies
human monoclonal
antibodies
monoclonal
Prior art date
Application number
DK05769838.3T
Other languages
Danish (da)
English (en)
Inventor
Herrera José M Carballido
Vries Jan E De
Christoph Schwaerzler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35457817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1817343(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0417306A external-priority patent/GB0417306D0/en
Priority claimed from GB0417301A external-priority patent/GB0417301D0/en
Priority claimed from GB0417304A external-priority patent/GB0417304D0/en
Priority claimed from GB0417302A external-priority patent/GB0417302D0/en
Priority claimed from GB0417305A external-priority patent/GB0417305D0/en
Priority claimed from GB0417303A external-priority patent/GB0417303D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1817343T3 publication Critical patent/DK1817343T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/247IL-4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
DK05769838.3T 2004-08-03 2005-08-02 Humane monoklone antistoffer mod humant IL-4 DK1817343T3 (da)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0417306A GB0417306D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417301A GB0417301D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417304A GB0417304D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417302A GB0417302D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417305A GB0417305D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417303A GB0417303D0 (en) 2004-08-03 2004-08-03 Organic compounds
PCT/EP2005/008361 WO2006013087A1 (en) 2004-08-03 2005-08-02 Human monoclonal antibodies against human il-4

Publications (1)

Publication Number Publication Date
DK1817343T3 true DK1817343T3 (da) 2014-09-15

Family

ID=35457817

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05769838.3T DK1817343T3 (da) 2004-08-03 2005-08-02 Humane monoklone antistoffer mod humant IL-4

Country Status (29)

Country Link
US (2) US7740843B2 (es)
EP (2) EP2327726A3 (es)
JP (1) JP4808712B2 (es)
KR (1) KR101245996B1 (es)
CN (1) CN101001877B (es)
AR (1) AR050044A1 (es)
AU (1) AU2005268932B2 (es)
BR (1) BRPI0514124B8 (es)
CA (1) CA2574289C (es)
CY (1) CY1115524T1 (es)
DK (1) DK1817343T3 (es)
EC (1) ECSP077222A (es)
ES (1) ES2504415T3 (es)
HK (1) HK1109158A1 (es)
HR (1) HRP20140888T1 (es)
IL (1) IL180789A (es)
MA (1) MA28981B1 (es)
MX (1) MX2007001342A (es)
MY (1) MY141851A (es)
NO (1) NO20070854L (es)
NZ (1) NZ552637A (es)
PE (1) PE20060560A1 (es)
PL (1) PL1817343T3 (es)
PT (1) PT1817343E (es)
SG (1) SG155177A1 (es)
SI (1) SI1817343T1 (es)
TN (1) TNSN07036A1 (es)
TW (1) TWI356828B (es)
WO (1) WO2006013087A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1868647A4 (en) * 2005-03-24 2009-04-01 Millennium Pharm Inc OV064 BINDING ANTIBODIES AND METHOD FOR THEIR USE
US8759490B2 (en) 2005-03-24 2014-06-24 Millennium Pharamaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US20110014117A1 (en) * 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
RU2624027C2 (ru) 2010-04-23 2017-06-30 Дженентек, Инк. Получение гетеромультимерных белков
CA2825064C (en) 2011-02-04 2022-08-30 Genentech, Inc. Fc variants and methods for their production
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
CN108409860B (zh) * 2017-02-10 2021-10-15 三生国健药业(上海)股份有限公司 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
KR20210136071A (ko) 2019-03-06 2021-11-16 리제너론 파아마슈티컬스, 인크. 암을 치료하는데 있어서 증진된 효능을 위한 il-4/il-13 경로 억제제
MA55372A (fr) 2019-03-21 2022-01-26 Regeneron Pharma Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie
CN114957472B (zh) * 2020-06-22 2023-10-31 南京融捷康生物科技有限公司 抗IL-4Rα的单域抗体以及应用和药物
US20230220089A1 (en) 2021-12-30 2023-07-13 Regeneron Pharmaceuticals, Inc. Methods for attenuating atopic march by administering an il-4/il-13 antagonist

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
KR900700132A (ko) 1988-02-02 1990-08-11 에릭 에스. 딕커 면역 글로불린 e 반응 억제 방법
AU639754B2 (en) * 1989-12-20 1993-08-05 Schering Corporation Antibody antagonists of human interleukin-4
SG52215A1 (en) * 1992-02-19 1998-09-28 Schering Corp Cloning and expresssion of humanized monoclonal antibodies against human interleukin-4
HU220103B (hu) 1992-08-20 2001-10-28 Schering-Plough Corp. IL-10 új alkalmazása
CA2171336C (en) * 1993-09-07 2011-06-21 Stephen Dudley Holmes Recombinant il4 antibodies useful in treatment of il4 mediated disorders
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US20020002132A1 (en) * 2000-05-26 2002-01-03 Pluenneke John D. Use of interleukin-4 antagonists and compositions thereof
EP1590364B1 (en) 2002-12-16 2011-10-05 Genmab A/S Human monoclonal antibodies against interleukin 8 (il-8)
FR2859725B1 (fr) * 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine

Also Published As

Publication number Publication date
CY1115524T1 (el) 2017-01-04
SG155177A1 (en) 2009-09-30
MA28981B1 (fr) 2007-11-01
NZ552637A (en) 2010-02-26
AU2005268932A1 (en) 2006-02-09
AU2005268932B2 (en) 2009-06-25
IL180789A (en) 2017-01-31
CA2574289A1 (en) 2006-02-09
SI1817343T1 (sl) 2014-09-30
US20100254993A1 (en) 2010-10-07
ES2504415T3 (es) 2014-10-08
US7740843B2 (en) 2010-06-22
PL1817343T3 (pl) 2014-11-28
TWI356828B (en) 2012-01-21
HRP20140888T1 (hr) 2014-10-24
JP2008507985A (ja) 2008-03-21
TNSN07036A1 (en) 2008-06-02
CA2574289C (en) 2014-09-16
EP1817343A1 (en) 2007-08-15
PT1817343E (pt) 2014-09-09
CN101001877B (zh) 2012-09-26
MY141851A (en) 2010-07-16
EP1817343B1 (en) 2014-06-25
BRPI0514124B1 (pt) 2017-01-31
JP4808712B2 (ja) 2011-11-02
EP2327726A2 (en) 2011-06-01
EP2327726A3 (en) 2012-07-11
CN101001877A (zh) 2007-07-18
PE20060560A1 (es) 2006-06-27
ECSP077222A (es) 2007-03-29
KR101245996B1 (ko) 2013-03-20
MX2007001342A (es) 2007-04-02
IL180789A0 (en) 2007-06-03
KR20070047299A (ko) 2007-05-04
WO2006013087A8 (en) 2007-03-01
BRPI0514124A (pt) 2008-05-27
AR050044A1 (es) 2006-09-20
TW200617024A (en) 2006-06-01
WO2006013087A1 (en) 2006-02-09
NO20070854L (no) 2007-04-24
BRPI0514124B8 (pt) 2021-05-25
HK1109158A1 (en) 2008-05-30
US20080241160A1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
DK1817343T3 (da) Humane monoklone antistoffer mod humant IL-4
CY2016016I1 (el) Ανθρωπινο αντισωμα αντι-υποδοχεα επιδερμικου αυξητικου παραγοντα
ATE484525T1 (de) Modifizierte humane igf-1r antikörper
NO20052889D0 (no) Humane monoklonale antistoffer mot CD25
DK1960434T3 (da) Monoklonale, humane antistoffer mod Fucosyl-GM1 og fremgangsmåder til anvendelse af anti-Fucosyl-GM1
CY2016035I2 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
NO20071430L (no) Anti-OX4OL antistoffer
DK2115003T3 (da) Humane antistoffer mod human delta-lignende ligand 4
DK2327423T3 (da) Humane antistoffer mod humant interleukin-22 (IL-22)
DK1844074T3 (da) Humane antistoffer og proteiner
ATE465180T1 (de) Therapeutische anti-igfr1-antikörper- kombinationen
CY2015030I1 (el) Ανταγωνιστικα αντισωματα il-17
IL191340A (en) Monoclonal antibodies against e8o
DK2177537T3 (da) Antistoffer til MAdCAM
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
IS3021B (is) Mótefni gegn M-CSF
CY2013046I1 (el) Καινοτομος χρηση των αντισωματων αντι il-1bhta
DK3156422T3 (da) Humane højaffinitetsantistoffer mod pcsk9
DK1737891T3 (da) Anti-p-selectin-antistoffer
DK2292663T3 (da) Antagonistiske human-let-specifikke, humane monoklonale antistoffer
DK1599504T3 (da) Modificeret antistof
DK1809660T3 (da) Thymus-specifikt protein
BRPI0509495A2 (pt) anticorpo humanizado
ITRM20040105A1 (it) Anticorpo monoclonale antitenascina umana.
ZA200804254B (en) Human monoclonal antibodies to O8E